OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Drug Discovery is 86. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Engineering precision nanoparticles for drug delivery	3306
Natural products in drug discovery: advances and opportunities	2084
Advances in oligonucleotide drug delivery	1062
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy	1026
PROTAC targeted protein degraders: the past is prologue	983
Trends in peptide drug discovery	852
Noncoding RNA therapeutics — challenges and potential solutions	764
Emerging concepts in the science of vaccine adjuvants	641
mRNA vaccines for infectious diseases: principles, delivery and clinical translation	611
RAS-targeted therapies: is the undruggable drugged?	574
Kinase drug discovery 20 years after imatinib: progress and future directions	513
Macrophages as tools and targets in cancer therapy	502
Targeting inflammation in atherosclerosis — from experimental insights to the clinic	473
Organs-on-chips: into the next decade	464
Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing	450
Evolution of the COVID-19 vaccine development landscape	437
Strategies for delivering therapeutics across the blood–brain barrier	435
Targeting cancer metabolism in the era of precision oncology	407
Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine	404
Radiopharmaceutical therapy in cancer: clinical advances and challenges	388
Anti-obesity drug discovery: advances and challenges	376
Trends in kinase drug discovery: targets, indications and inhibitor design	350
Channelling inflammation: gasdermins in physiology and disease	343
Antisense technology: an overview and prospectus	311
B cell depletion therapies in autoimmune disease: advances and mechanistic insights	309

FDA approves 100th monoclonal antibody product	298
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics	288
The clinical landscape for AAV gene therapies	285
Poly(ADP-ribose) polymerase inhibition: past, present and future	282
Therapeutically harnessing extracellular vesicles	278
Targeting the epigenetic regulation of antitumour immunity	275
The quest to slow ageing through drug discovery	261
Navigating CAR-T cells through the solid-tumour microenvironment	248
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease	245
Targeted protein degraders crowd into the clinic	241
Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target	234
PI3K inhibitors are finally coming of age	232
Base editing: advances and therapeutic opportunities	229
Kinase inhibition in autoimmunity and inflammation	228
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans	226
Beyond immune checkpoint blockade: emerging immunological strategies	218
Advances in covalent drug discovery	214
Advances in TRP channel drug discovery: from target validation to clinical studies	212
The foundations of immune checkpoint blockade and the ipilimumab approval decennial	211
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials	208
Image-based profiling for drug discovery: due for a machine-learning upgrade?	202
Emerging therapeutic opportunities for integrin inhibitors	199
Protein arginine methylation: from enigmatic functions to therapeutic targeting	192
Identification of neoantigens for individualized therapeutic cancer vaccines	188
Pharmacological targeting of endoplasmic reticulum stress in disease	180
Circadian rhythm as a therapeutic target	178
Drugging p53 in cancer: one protein, many targets	173
Function and therapeutic value of astrocytes in neurological diseases	173
Targeting HER2-positive breast cancer: advances and future directions	170
Targeting RNA structures with small molecules	167
Therapeutic strategies targeting FOXO transcription factors	166
Advances in targeting ‘undruggable’ transcription factors with small molecules	163
Antitumour dendritic cell vaccination in a priming and boosting approach	151
Targeting Notch in oncology: the path forward	146
Engineering living therapeutics with synthetic biology	145
Therapeutic strategies for COVID-19: progress and lessons learned	143
2020 FDA drug approvals	141
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities	141
Lipogenesis inhibitors: therapeutic opportunities and challenges	132
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies	123
Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease	119
The PROTACtable genome	119
The emerging role of mass spectrometry-based proteomics in drug discovery	118
Targeting co-stimulatory molecules in autoimmune disease	110
Engineering the next generation of cell-based therapeutics	108
Exosome-based candidates move into the clinic	104
Drugging the efferocytosis process: concepts and opportunities	101
Modulating biomolecular condensates: a novel approach to drug discovery	99
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	98
Antibody–drug conjugates come of age in oncology	98

Impact of COVID-19 on oncology clinical trials	97
Immune targets for therapeutic development in depression: towards precision medicine	97
Combinations take centre stage in PD1/PDL1 inhibitor clinical trials	96
The glomerular filtration barrier: a structural target for novel kidney therapies	93
Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation	92
Targeting replication stress in cancer therapy	92
A tale of two antiviral targets — and the COVID-19 drugs that bind them	91
Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs	87
Improving target assessment in biomedical research: the GOT-IT recommendations	86
Phenotypic drug discovery: recent successes, lessons learned and new directions	86
The promises and perils of psychedelic pharmacology for psychiatry	86